CAS |
209783-80-2 |
Chinese Name |
恩替诺特 |
English Name |
Entinostat |
Synonym |
恩替诺特;TCV-116;SNDX-275;恩替诺特;路通;维生素P; |
Unit |
Bottle |
Purity |
≥98% |
Molecular Formula |
C21H20N4O3 |
Molecular Weight |
376.41 |
Appearance |
White to yellow solid |
Storage |
Powder : -20℃, 2 years;In solvent(mother liquid): -20℃, 1 month; -80℃, 6 months |
Solubility |
Soluble in DMSO≥5mg/ml |
MDL |
MFCD08272435 |
InChIKey |
INVTYAOGFAGBOE-UHFFFAOYSA-N |
InChI |
InChI=1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26) |
PubChem CID |
4261 |
SMILES |
O=C(NCC1=CC=C(C=C1)C(NC2=CC=CC=C2N)=O)OCC3=CC=CN=C3 |
Description |
Entinostat is a selective HDAC class I inhibitor. |
Target Point |
HDAC |
Passage |
DNA Damage/DNA Repair;Epigenetics;NF-κB |
IC50 |
HDAC1:243 nM ; HDAC3:248 nM ; HDAC2:453 nM [1-4] |
Data Literature Source |
[1]. Lauffer BE, et al. Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability. J Biol Chem. 2013 Sep 13;288(37):26926-43.
[2]. Rosato RR, et al. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res. 2003 Jul 1;63(13):36
[3]. Saito A, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A, 1999, 96(8), 4592-4597.
[4]. Zhang ZY, et al. MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis. Neurosci, 2010, 169, 370-377. |
Specification |
10mg 50mg 100mg |